Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis.

A post hoc analysis from the ORAL Surveillance study reported a nearly significant higher MACE risk with tofacitinib 5 mg BID (8.3%; 17/204) and 10 mg BID (7.7%; 17/222) compared to TNF inhibitors in patients with rheumatoid arthritis and a history of atherosclerotic cardiovascular disease (HR 1.98, 95% CI 0.95–4.14, p = 0.196); the highest risk was associated with age > 50 years and at least one additional cardiovascular (CV) risk [ 46 ].

also in 3,287 other papers